Abstract: SA-PO1141
Treatment Strategies in De Novo and Recurrent Hyperkalemia: TRACK Study Insights
Session Information
- CKD: Progression, Drugs, Modalities, and Environmental Factors
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention
Authors
- Ferraro, Pietro Manuel, Universita degli Studi di Verona, Verona, Veneto, Italy
- Shivappa, Nitin, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, United States
- Bakhai, Ameet, Barnet General Hospital, Royal Free London NHS Foundation Trust, London, Barnet, United Kingdom
- Bover, Jordi, Hospital Universitari Germans Trias i Pujol, Barcelona, CT, Spain
- Butler, Javed, Baylor Scott & White Research Institute, Dallas, Texas, United States
- Fried, Linda F., VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States
- Schneider, Markus P., University Hospital Erlangen, Erlangen, Germany
- Tangri, Navdeep, University of Manitoba, Winnipeg, Manitoba, Canada
- Winkelmayer, Wolfgang C., Baylor College of Medicine, Houston, Texas, United States
- Bishop, Meredith S., AstraZeneca Pharmaceuticals LP, Gaithersburg, Maryland, United States
- Chen, Hungta (Tony), AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, United States
- Sundin, Anna-Karin, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
- Bonaca, Marc P., University of Colorado, Aurora, Colorado, United States
- Hsia, Judith, University of Colorado, Aurora, Colorado, United States
Background
Effective HK management is vital to reduce life-threatening HK-associated events. Real-world evidence is needed to elucidate the characteristics and treatment patterns of patients with HK, aiding guideline adherence and optimizing care. The longitudinal TRACK study examines HK management strategies, objectives, and outcomes over 12 months in five countries.
Methods
TRACK included 1330 patients with HK (K+>5.0 mmol/L) from Germany, Italy, Spain, the UK, and the US. De novo† and recurrent† HK cases were assessed at 3-month intervals.
Results
The de novo group (n=458) had lower CKD only prevalence vs the recurrent group (n=870; P<0.0001; Table). Across 12 months, conservative treatment was the most common HK management strategy but tended to decline over time. Similar trends were seen for K+ binder use. Overall, “ease of treatment” and “lower K+ levels to normal range” were the most common HK treatment objective and expectation, respectively. First occurrence of K+ normalization at follow-up was higher in the recurrent vs de novo group (P=0.0005; Table). Continuation of RAASi therapy increased from baseline to Month 12 in the de novo group and was significantly higher at Month 12 vs recurrent group (P<0.0001). The incidence of cumulative HK complications was higher in the recurrent vs de novo group (P=0.0008; Table).
Conclusion
We observed similar trends in HK treatment strategies in de novo and recurrent cases, associated with suboptimal K+ normalization and RAASi use. HK management trended towards conservative approaches despite guideline recommendations, highlighting treatment gaps and the need for enhanced HK care standards.
Funding
- Commercial Support – AstraZeneca